MAPK10 and HNRNPK

Number of citations of the paper that reports this interaction (PubMedID 11231586)
90

Data Source:
HPRD (in vitro)

		MAPK10	HNRNPK
Description		mitogen-activated protein kinase 10	heterogeneous nuclear ribonucleoprotein K
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Cytoplasm Mitochondrion Cytosol Plasma Membrane Neuron Projection Perikaryon Glutamatergic Synapse	Nuclear Chromatin Podosome Nucleus Nucleoplasm Cytoplasm Focal Adhesion Cytoplasmic Stress Granule Membrane Cell Projection Extracellular Exosome Catalytic Step 2 Spliceosome
	Molecular Function	JUN Kinase Activity MAP Kinase Activity MAP Kinase Kinase Activity Protein Binding ATP Binding	RNA Polymerase II Proximal Promoter Sequence-specific DNA Binding DNA-binding Transcription Activator Activity, RNA Polymerase II-specific Single-stranded DNA Binding RNA Binding Protein Binding Protein Domain Specific Binding Identical Protein Binding Cadherin Binding
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Activation Of MAPK Activity Protein Phosphorylation Signal Transduction JNK Cascade JUN Phosphorylation Response To Water Deprivation Response To Light Stimulus Regulation Of Gene Expression Intracellular Signal Transduction Fc-epsilon Receptor Signaling Pathway Regulation Of Circadian Rhythm Rhythmic Process Regulation Of DNA-binding Transcription Factor Activity Cellular Hyperosmotic Response Neurotransmitter Receptor Transport To Postsynaptic Membrane Vesicle-mediated Transport In Synapse	MRNA Splicing, Via Spliceosome RNA Processing Signal Transduction Regulation Of Low-density Lipoprotein Particle Clearance Viral Process RNA Metabolic Process Negative Regulation Of Apoptotic Process Positive Regulation Of Low-density Lipoprotein Particle Receptor Biosynthetic Process Positive Regulation Of Transcription By RNA Polymerase II Negative Regulation Of MRNA Splicing, Via Spliceosome Positive Regulation Of Receptor-mediated Endocytosis Regulation Of Intrinsic Apoptotic Signaling Pathway In Response To DNA Damage By P53 Class Mediator
Pathways		Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors	SUMOylation of RNA binding proteins mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA HCMV Late Events
Drugs		2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine 9-(4-Hydroxyphenyl)-2,7-Phenanthroline Phosphoaminophosphonic Acid-Adenylate Ester N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline	Artenimol Phenethyl Isothiocyanate
Diseases
GWAS		Cleft lip with or without cleft palate x maternal periconceptional smoking interaction (parent of origin effect) ( 31372216) Cobalt levels ( 26025379) Diisocyanate-induced asthma ( 25918132) Gait speed in old age ( 28077804) Liver enzyme levels (alanine transaminase) ( 22001757) Multiple sclerosis ( 31604244) Peripheral artery disease ( 25009551) Response to cytidine analogues (gemcitabine) ( 24483146)	Body fat distribution (leg fat ratio) ( 30664634) Body fat distribution (trunk fat ratio) ( 30664634)
Interacting Genes		38 interacting genes: APP ARRB1 ARRB2 ATF2 BCL2L11 CDK5 CDKN1B CDKN2A CDKN2C CEP290 CREBBP DUSP10 DUSP16 DUSP9 ELK1 FBXO7 GTF3C1 HAX1 HDAC9 HNRNPK HRAS JUN KIF26A LDHA MAP2K4 MAPK8IP2 MAPK8IP3 MAPKBP1 MAPT MCL1 PKMYT1 PLIN2 RELA SH3BP5 STMN2 TNIP1 TP53 UNC119	115 interacting genes: ABI2 APBB1 AQP5 AURKA BTRC C6orf226 CBLB CCAR1 CCDC33 CDKN1A CEBPB CIRBP CMTM5 CNNM3 CSK CTNNBL1 DALRD3 DDX1 DDX17 DDX5 DHX9 DIDO1 DOCK2 EIF3F ELAVL1 FBXL18 FBXO7 FBXW7 FYN GFI1B GRAP2 GRB2 GZMA GZMK H3-4 HCK HMGB1 HNRNPA0 HNRNPD HNRNPL HNRNPLL ITK ITSN2 KHDRBS1 KHDRBS2 KHDRBS3 LYN MAPK10 MARK4 MATR3 MDM2 NCK2 NEDD4 NPDC1 PABPC1 PCBP1 PCBP2 PCDHB14 PCGF3 PELI2 PIN1 PPP1R10 PRKCD PRMT1 PRPF31 PRPF40A PRR3 QKI RALY RASD1 RBFOX2 RBM10 RBM14 RBM3 RBM4 RBM41 RBM42 RBM7 RBMX RBMY1A1 RBMY1F RNA18SN5 RNA28SN5 RTP5 SAFB SF1 SMAD3 SNRPA SORBS3 SPG7 SRC SREK1 SRPK2 SRRT SRSF3 SUMO1 SUMO2 SYNCRIP TBP TCERG1 TERF2IP TYK2 U2AF1 UBE2I VAV1 WBP4 WWOX YBX1 YTHDC1 YWHAQ ZFC3H1 ZNF385C ZNF688 ZNF792 ZNRF2P1
Entrez ID		5602	3190
HPRD ID		04207	02834
Ensembl ID		ENSG00000109339	ENSG00000165119
Uniprot IDs		A0A1P0B7D2 A0A286YEQ7 A0A286YES0 A0A286YF02 A0A286YF97 A0A286YFD7 A0A286YFN2 D6RCB1 D6RJF9 F8W9R5 I6L9F3 P53779 Q499Y8	B4DUQ1 P61978
PDB IDs		1JNK 1PMN 1PMU 1PMV 2B1P 2EXC 2O0U 2O2U 2OK1 2P33 2R9S 2WAJ 2ZDT 2ZDU 3CGF 3CGO 3DA6 3FI2 3FI3 3FV8 3G90 3G9L 3G9N 3KVX 3OXI 3OY1 3PTG 3RTP 3TTI 3TTJ 3V6R 3V6S 4H36 4H39 4H3B 4KKE 4KKG 4KKH 4U79 4W4V 4W4W 4W4X 4W4Y 4WHZ 4X21 4Y46 4Y5H 4Z9L 6EKD 6EMH 6EQ9	1J5K 1KHM 1ZZI 1ZZJ 1ZZK
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?